文献速递冠心病

FABOLUS-FASTER试验:坎格瑞洛、替罗非班与嚼服或整片普拉格雷在STEMI患者中的主要结果

Cangrelor, Tirofiban, and Chewed or Standard Prasugrel Regimens in Patients With ST-Segment-Elevation Myocardial Infarction: Primary Results of the FABOLUS-FASTER Trial.
PubMed 文献 · Circulation · 2020-06-27

FABOLUS-FASTER是一项多中心、开放标签、随机研究,纳入122例未用过P2Y12抑制剂的STEMI患者,随机分为坎格瑞洛组、替罗非班组合普拉格雷60mg负荷组(再随机分为嚼服与整片吞服)。主要终点为30分钟时20μmol/L ADP诱导的IPA。结果显示替罗非班IPA优于坎格瑞洛;坎格瑞洛和替罗非班均优于嚼服普拉格雷;嚼服普拉格雷较整片吞服未提高IPA,但活性代谢物浓度更高。

要点

  • 替罗非班30分钟IPA优于坎格瑞洛(95.0±8.9 vs 34.1±22.5,P<0.001)。
  • 坎格瑞洛和替罗非班IPA均优于嚼服普拉格雷(10.5±11.0,P均<0.001)。
  • 嚼服普拉格雷较整片吞服未提高IPA(6.3±11.4,P=0.47)。

核心结论

  • 坎格瑞洛的IPA劣于替罗非班;两者均优于嚼服普拉格雷;嚼服普拉格雷未优于整片普拉格雷。

研究设计与样本

  • 多中心、开放标签、随机研究,纳入122例未用过P2Y12抑制剂的STEMI患者,按1:1:1随机分三组。
  • 坎格瑞洛组n=40,替罗非班组n=40(均为弹丸注射+2小时输注后60mg普拉格雷),普拉格雷60mg负荷组n=42(再1:1随机分嚼服n=21与整片n=21)。
  • 主要终点为30分钟时20μmol/L ADP诱导的IPA(光透射聚集法)。

主要发现

  • 30分钟IPA:替罗非班95.0±8.9 vs 坎格瑞洛34.1±22.5,P<0.001,坎格瑞洛未达到非劣效(界值9%)。
  • 坎格瑞洛或替罗非班均优于嚼服普拉格雷(IPA 10.5±11.0,P均<0.001)。
  • 嚼服普拉格雷与整片普拉格雷IPA无差异(6.3±11.4,P=0.47)。
  • 嚼服普拉格雷活性代谢物浓度高于整片(62.3±82.6 vs 17.1±43.5 ng/mL,P=0.016)。

临床怎么用

  • STEMI直接PCI患者中,如需快速起效的抗血小板作用,替罗非班可能提供比坎格瑞洛更高的早期IPA。
  • 嚼服普拉格雷虽提高活性代谢物浓度,但未改善30分钟IPA,不支持以此作为快速起效常规策略。

局限性

  • 开放标签设计,样本量小(共122例),结果需谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Standard administration of newer oral P2Y12 inhibitors, including prasugrel or ticagrelor, provides suboptimal early inhibition of platelet aggregation (IPA) in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention. We aimed to investigate the effects of cangrelor, tirofiban, and prasugrel, administered as chewed or integral loading dose, on IPA in patients undergoing primary percutaneous coronary intervention. METHODS: The FABOLUS-FASTER trial (Facilitation Through Aggrastat or Cangrelor Bolus and Infusion Over Prasugrel: A Multicenter Randomized Open-Label Trial in Patients with ST-Elevation Myocardial Infarction Referred for Primary Percutaneous Intervention) is an investigator-initiated, multicenter, open-label, randomized study. A total of 122 P2Y12-naive patients with ST-segment-elevation myocardial infarction were randomly allocated (1:1:1) to cangrelor (n=40), tirofiban (n=40) (both administered as bolus and 2-hour infusion followed by 60 mg of prasugrel), or 60-mg loading dose of prasugrel (n=42). The latter group underwent an immediate 1:1 subrandomization to chewed (n=21) or integral (n=21) tablets administration. The trial was powered to test 3 hypotheses (noninferiority of cangrelor compared with tirofiban using a noninferiority margin of 9%, superiority of both tirofiban and cangrelor compared with chewed prasugrel, and superiority of chewed prasugrel as compared with integral prasugrel, each with α=0.016 for the primary end point, which was 30-minute IPA at light transmittance aggregometry in response to 20 μmol/L adenosine diphosphate. RESULTS: At 30 minutes, cangrelor did not satisfy noninferiority compared with tirofiban, which yielded superior IPA over cangrelor (95.0±8.9 versus 34.1±22.5; P<0.001). Cangrelor or tirofiban were both superior to chewed prasugrel (IPA, 10.5±11.0; P<0.001 for both comparisons), which did not provide higher IPA over integral prasugrel (6.3±11.4; P=0.47), despite yielding higher prasugrel active metabolite concentration (ng/mL; 62.3±82.6 versus 17.1±43.5; P=0.016). CONCLUSIONS: Cangrelor provided inferior IPA compared with tirofiban; both treatments yielded greater IPA compared with chewed prasugrel, which led to higher active metabolite concentration but not greater IPA compared with integral prasugrel. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT02978040; URL: https://www.clinicaltrialsregister.eu; EudraCT 2017-001065-24.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Gargiulo G, Esposito G, Avvedimento M, et al. Cangrelor, Tirofiban, and Chewed or Standard Prasugrel Regimens in Patients With ST-Segment-Elevation Myocardial Infarction: Primary Results of the FABOLUS-FASTER Trial. Circulation. 2020. PMID: 32795098. doi:10.1161/CIRCULATIONAHA.120.046928

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。